MFSD2A gene maps on chromosome 1p34, within a linkage disequilibrium block containing genetic elements associated with progression of lung cancer, even if with some discrepancies in Asian and Caucasian populations attributable to ethnic differences in allelic frequencies of the functional genetic variations mapping in this locus. Here we show that MFSD2A expression is strongly downregulated in non-small cell lung cancer cell lines of different histotypes and in primary lung adenocarcinomas. Investigating, by luciferase reporter assay, three single nucleotide polymorphisms (SNPs), mapping in MFSD2A 5’-regulatory region, for their putative effects on gene transcription, we find that rs12072037 SNP (polymorphic in Asians, but not in Caucasian) is able to modulate transcriptional activity of MFSD2A promoter in cell lines expressing transcription factors potentially binding to the SNP site. Microarray analysis showed that MFSD2A upregulation modulates transcript levels of genes involved in cell cycle control and interaction with the extracellular matrix. Exogenous expression of MFSD2A induced a significant reduction of tumour colony number in vitro and tumour volume in vivo. In addition, lung tumour cells transfected with MFSD2A were blocked at the G1 phase of cell cycle progression and showed impaired adhesion and migration in vitro. Together, these data suggest that MFSD2A is a novel tumour suppressor gene that regulates cell cycle progression and matrix attachment. The functional variation in MFSD2A 5’-region influencing promoter activity may be involved in modulation of MFSD2A transcript levels in normal and lung tumours, and be associated with lung cancer progression.
. 2010 Sep 24;4(Suppl 2):P55.
MFSD2A is a novel lung tumour suppressor gene whose expression is modulated by a 5’-region polymorphism
Francesca Colombo
1,✉, Monica Spinola
1,2, Felicia S Falvella
1, James P Sullivan
2, David S Shames
2, Luc Girard
2, Paola Spessotto
3, John D Minna
2, Tommaso A Dragani
1
Francesca Colombo
1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Find articles by Francesca Colombo
Monica Spinola
1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
2University of Texas Southwestern Medical Center, Dallas, TX, USA
Find articles by Monica Spinola
Felicia S Falvella
1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Find articles by Felicia S Falvella
James P Sullivan
2University of Texas Southwestern Medical Center, Dallas, TX, USA
Find articles by James P Sullivan
David S Shames
2University of Texas Southwestern Medical Center, Dallas, TX, USA
Find articles by David S Shames
Luc Girard
2University of Texas Southwestern Medical Center, Dallas, TX, USA
Find articles by Luc Girard
Paola Spessotto
3Centro di Riferimento Oncologico di Aviano, Aviano, Italy
Find articles by Paola Spessotto
John D Minna
2University of Texas Southwestern Medical Center, Dallas, TX, USA
Find articles by John D Minna
Tommaso A Dragani
1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Find articles by Tommaso A Dragani
1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
2University of Texas Southwestern Medical Center, Dallas, TX, USA
3Centro di Riferimento Oncologico di Aviano, Aviano, Italy
✉
Corresponding author.
Supplement
Abstracts of the 16th International Charles Heidelberger Symposium on Cancer ResearchAna M Urbano, A J Guiomar, Carlos F Oliveira, Isabel M Carreira and Maria C AlpoimThe 16th International Charles Heidelberger Symposium on Cancer Research thanks ACIMAGO, BPI, FCT, FLAD, Pfizer, Fundação Champalimaud, Alfagene, Reagente 5 and Câmara Municipal de Montemor o Velho who sponsor this Symposium.http://www.biomedcentral.com/content/pdf/1753-6561-4-S2-info.pdf
Conference
26-28 September 2010
16th International Charles Heidelberger Symposium on Cancer Research
Coimbra, Portugal
Collection date 2010.
Copyright ©2010 Colombo et al; licensee BioMed Central Ltd.
PMCID: PMC3255054
